 This trial will include patients who are not candidates for transplantation and above the age of 55. Treatment cycles will include MPmelphalan 9 mg sq.mday d1-4, prednisolone 60 mgsq.md,d1-4 every six weeks for maximum 8 cycles. Patients will be randomised to MPT Thalidomide 1:1 100 mgday continuously. Cross-over to MPT is allowed if insufficient response is obtained in the MP arm. response will be evaluated every other cycle. At the end of 12 months of treatment patients will be followed until progress and death. Second line treatment is not defined. 